Business

Announcement on Voluntary Disclosure of Publicity of Furmonertinib Mesilate Tablets for First-line Indication Treatment of EGFR20 Exon Insertion Mutated NSCLC Included in Potential Breakthrough Therapy Variety

Announcement on Voluntary Disclosure of Publicity of Furmonertinib Mesilate Tablets for First-line Indication Treatment of EGFR20 Exon Insertion Mutated NSCLC Included in Potential Breakthrough Therapy Variety

articleShanghai Allist Pharmaceuticals Co. Ltd. Class AJanuary 8, 20243/news/announcement-on-voluntary-disclosure-of-publicity-of-furmonertinib-mesilate-tablets-for-first-line-indication-treatment-of-egfr20-exon-insertion-mutated-nsclc-included-in-potential-breakthrough-therapy-variety
Announcement on Voluntary Disclosure of Publicity of Furmonertinib Mesilate Tablets for First-line Indication Treatment of EGFR20 Exon Insertion Mutated NSCLC Included in Potential Breakthrough Therapy Variety

About this update from Shanghai Allist Pharmaceuticals Co. Ltd. Class A

Announcement on Voluntary Disclosure of Publicity of Furmonertinib Mesilate Tablets for First-line Indication Treatment of EGFR20 Exon Insertion Mutated NSCLC Included in Potential Breakthrough Therapy VarietyThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference:" target="_blank">View Attachment

View stock analysis, news, and events for Shanghai Allist Pharmaceuticals Co. Ltd. Class A